Search results
Results from the Tech24 Deals Content Network
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer 's off-patent medicine division, to form Viatris. [ 1] Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK [ 2] and a "Global Center" in Canonsburg ...
Viatris' goal is to become a thinner, leaner company focused on higher growth opportunities, hence the divestitures, which recently ended with the company finalizing the spin-off of its over-the ...
Pfizer Inc. ( / ˈfaɪzər / FY-zər) [ 3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
Falling by about 23% right after the news, and down around 32.5% in the past month, it may take some time for Viatris to bounce back. Another generic drug maker, Teva Pharmaceutical (NYSE:TEVA ...
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and ...
An epinephrine autoinjector (or adrenaline autoinjector, also known by the trademark EpiPen) is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.
Pfizer agreed last year to settle for $345 million. Teva was not a defendant. Separately, India's Biocon Ltd on Monday announced a $3.34 billion deal for Viatris' biosimilars business.